Lupin Announces Acquisition of Nanomi B.V.
News Feb 18, 2014
Lupin Limited has announced the acquisition of Nanomi B.V. in the Netherlands. With this acquisition, Lupin has made its foray into the technology intensive complex injectables space.
Nanomi has patented technology platforms to develop complex injectable products. Nanomi has a rich talent pool of scientists who would be backed by Lupin's global R&D and manufacturing teams.
Commenting on the acquisition Ms. Vinita Gupta, Chief Executive Officer, Lupin Limited said "We are very pleased with the acquisition of Nanomi. With the use of Nanomi's proprietary technology platform, Lupin would be able to make significant in-roads into the niche area of complex injectables."
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019